Journal article
Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives
D Eratne, S Janelidze, CB Malpas, S Loi, M Walterfang, A Merritt, I Diouf, K Blennow, H Zetterberg, B Cilia, C Wannan, C Bousman, I Everall, A Zalesky, M Jayaram, N Thomas, SF Berkovic, O Hansson, D Velakoulis, C Pantelis Show all
Australian and New Zealand Journal of Psychiatry | SAGE PUBLICATIONS LTD | Published : 2022
Abstract
Objective: Schizophrenia, a complex psychiatric disorder, is often associated with cognitive, neurological and neuroimaging abnormalities. The processes underlying these abnormalities, and whether a subset of people with schizophrenia have a neuroprogressive or neurodegenerative component to schizophrenia, remain largely unknown. Examining fluid biomarkers of diverse types of neuronal damage could increase our understanding of these processes, as well as potentially provide clinically useful biomarkers, for example with assisting with differentiation from progressive neurodegenerative disorders such as Alzheimer and frontotemporal dementias. Methods: This study measured plasma neurofilament ..
View full abstractGrants
Awarded by Familjen Erling-Perssons Stiftelse
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: C.P. was supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1105825) and an NHMRC L3 Investigator Grant (1196508). Funding to A.S. was provided by Swedish federal government under the ALF agreement, Lund University, the Fredrik and Ingrid Thuring, Ellen and Henrik Sjobring and the Fromma Foundation for medical research. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21831376C, #ADSF-21-831381C and #ADSF-21-831377C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. This Study was also supported by: MACH MRFF RART 2.2, and Psychiatry and Rehabilitation Division, Region Skane, Sweden. The role of these funding sources was to support research study staff and biosample analyses.